Patented Procedures on Homologous Recombination

HR licenses

US patents US6528313, US6638768 and US6528314

These are the patents on procedures using homologous recombination methods, and:

  • Owned by Institut Pasteur
  • Exclusively licensed to Cellectis
  • Exclusively sublicensed to genOway for research applications using rodent models

 

Does this affect you?

You can access and read the patents at the US patent office database using the patent numbers 6528313, 6638768 and 6528314.

You are concerned when the targeting constructs used to create the model look anything like the image below, and:

  • You develop such a model in the US, or
  • You are using such a model in the US, or
  • You plan to third-party use such a model in the US, or
  • You plan to partner with US-based companies

HR licensed targeting constructs

 

Typical targeting construct protected by US6528313, US6638768, US6528314.

Two homologous recombination (HR) sequences span a coding sequence and/or regulatory sequence as well as a resistance gene under its proper promoter.

 

 

How to obtain your freedom to operate?

genOway is the only source for rights using this procedure of homologous recombination for R&D applications on genetically modified rodent models. 

Acquire the licence when:

  • Creating of a new Knockin model (read more)
  • Accessing material from international repositories, like IKMC (EUCOMM, KOMP, etc.) (read more)
  • Licensing a model from a third party (read more)
  • Using Knockin models not purchased from genOway (read more)

Neither transgenic companies nor academic centers can provide you with the rights for using rodent models developed by this homologous recombination-based method.

On January 31st  2014, genOway has acquired a worldwide exclusive license (see the press release) on the homologous recombination technology from Cellectis, including the following rights:

  • Exclusive service provider - To develop and sell research models using the Homologous Recombination Technology. Customers of genOway will obtain a complete and worldwide rights to use such models for their research programs including pharmaceutical research.
  • Exclusive distributor - Since thousands of research models have been developed using the Homologous Recombination Technology, genOway will enable both the model provider and the scientist using the model with all the rights needed to work together.
  • Exclusive sublicensing rights - A significant proportion of scientists are using models developed using the Homologous Recombination Technology with no right to do so. These models lack legality either because the model was created by internal facilities or because they purchased it from transgenic companies which both had no rights to transfer freedom to use to the end-user. genOway will license the needed rights (for past and/or future use) to these scientists. genOway and Cellectis are strongly committed to enable scientists to benefit from the technology and to prohibit unauthorized use of the technology.
    If a company or a transgenic platform states that they can provide you with such rights, do not hesitate to request from us a formal letter from Cellectis clarifying your status.

genOway customers and sublicensees will be able to acquire the following rights:

  • Basic research - Analyses of genes and their functions.
  • Biopharmaceutical research - Activities aiming at developing drugs, including but not limited to targeting validation and drug screening.
  • Biologics engineering - Discovery and engineering of biologics molecules, i.e. humanized mouse models for human antibody development.

Any other application is excluded, in particular any production of drugs for clinical phases, any industrial production, and diagnostic applications. Customers must request a sublicense from Cellectics for these purposes.

 

Licence for creating a new Knockin model

Which rights are provided with a model created with genOway?

Animal models developed with genOway will be delivered with all the necessary rights to use for research applications, which includes:

  • Rights to breed, intercross and modify the models.
  • Rights to use the model for basic research and for biopharmaceutical research like target validation, drug screening, pharmacological studies, etc.
  • Rights to use subcontractors like professional breeders and CROs.

All these rights are included in the price of the service. No other payment will be necessary: no success fee, no annual fee, etc.

Licence for using models from international repositories, like IMPC (EUCOMM, KOMP, etc.)

Most of these consortia have used numerous technologies when developing the materials. End users will need the appropriate rights to use these models, which includes the Homologous Recombination Technology, but also other technologies for which genOway is the exclusive licensee, like the IRES technology, the RMCE technology, the Flex technology, etc.

genOway's strategy is to provide the end-user with a guaranteed worldwide right to use these models covering all the technologies used.

Our standard conditions include:

  • Rights to breed, intercross and modify the models.
  • Rights to use the model for fundamental research and for commercial research like target validation, drug screening, pharmacological studies, etc.
  • Rights to use subcontractors like professional breeders and CROs.

All these rights are included in our standard contract. Financial conditions will vary from one source of models to another as well as on the size of the customer organization and the field of use (bulk conditions are available).
No other payment will be necessary: no success fee, no annual fee, etc.

In-license a model from a third party

Thousands of Knockin models have been developed and are available in laboratories and companies. This tremendous resource may contain a model of interest for your research programs.

genOway's strategy is to enable such distribution to occur by providing all necessary rights with reasonable conditions.

Our strategy is aimed at:

  • Facilitating distribution (MTA and license) of models within the scientific community including for-profit organizations.
  • Providing scientists with all the rights to use that they need before they perform their research experiments.

Our standard conditions include:

  • Rights to breed, intercross and modify the models.
  • Rights to use the model for fundamental research and for commercial research like target validation, drug screening, pharmacological studies, etc.
  • Rights to use subcontractors like professional breeders and CROs.

All these rights are included in the price of the distribution contract which ranges from 5000€ to 40,000€ per model for standard rights depending on the size of the customer organization and the field of use (bulk conditions are available).
No other payment will be necessary: no success fee, no annual fee, etc.

For more information on the agreement, please read the press release (PDF) or contact:

Dr Carteau
IP and licensing manager
Email: carteau(at)genoway(.)com

Licence for using Knockin models not purchased from genOway

Animal models developed with the Homologous Recombination Technology require a formal license to be used. Until now neither transgenic companies nor academic platforms were able to provide this worldwide rights to use.

Whatever the source of the model, the end-user is infringing when using such a model if he did not acquire a license (even though the provider of the model is the source of the infringement).

genOway's general objective is to support researchers by providing them with solutions. In this particular case, when scientists have used and/or are using models without rights, we provide as STANDARD conditions, the solution needed to "clean" the situation.

genOway can provide a standard non-exclusive license covering past uses and/or future uses, including all necessary rights:

  • Rights to breed, intercross and modify the models.
  • Rights to use the model for fundamental research and for commercial research like drug screening, pharmacological studies, etc.
  • Rights to use subcontractors like professional breeders and CROs.

License conditions are similar to the ones associated with a new model (see above) and does not contain any punitive clause. The one-time payment licensing fee ranges from 5000€ to 40,000€ per model for standard rights depending on the size of the customer organization and the field of use (bulk conditions are available).

Since our ultimate goal is to enable every scientist to benefit from the technology and not to limit its applications to exclusive partners or preferred customers, we offer a complete field of use and reasonable conditions. Nevertheless, to defend the rights of Pasteur Institute, the patent owner, and of our head licensee Cellectis, we are also committed to vigorously defend our rights if scientists who have created or used / are creating or using models developed with the Homologous Recombination Technology refuse to acquire a license.

For more information on the agreement, please read the press release (PDF) or contact:

Dr Carteau
IP and licensing manager
Email: carteau(at)genoway(.)com